Protagonist Therapeutics (PTGX) Tops Q4 EPS by 2c, Revenues Miss

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of ($0.63), $0.02 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.72 million versus the consensus estimate of $3.22 million.

"We are pleased to have made great progress in 2019, creating multiple opportunities to execute on our clinical development plans with three platform-generated therapeutic candidates," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. "Our priorities for 2020 include evaluating PTG-300 in multiple blood disorders with the intent of selecting the first clinical indication for a pivotal study, continuing Phase 2 development of PTG-200 with our partner Janssen Biotech, and advancing PN-943 into Phase 2 development in ulcerative colitis. Our financial position provides us with sufficient resources through the end of 2021 which should enable us to reach definitive conclusions for all of the ongoing clinical proof of concept studies."

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• WWP, Plc (WPP) Issues Q1 Trading Update
• Integer Holdings Corp (ITGR) Tops Q1 EPS by 2c ; Offers Guidance